Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 7/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211805 | 1.00 | USP2 (0.58) | USP2SLCO1B1SLC7A5GABRR1LMNA | |
| SCHEMBL6431831 | 1.00 | USP2 (0.58) | USP2SLCO1B1SLC7A5GABRR1LMNA | |
| SCHEMBL17054062 | 0.84 | — | — | |
| SCHEMBL31074088 | 0.84 | USP2 (0.50) | USP2SLCO1B1SLC7A5GABRR1LMNA | |
| SCHEMBL17047028 | 0.84 | — | — | |
| SCHEMBL23120067 | 0.84 | — | — | |
| SCHEMBL9060368 | 0.84 | — | — | |
| SCHEMBL14830311 | 0.81 | USP2 (0.54) | USP2SLCO1B1SLC7A5GABRR1SLC1A3 | |
| SCHEMBL16731973 | 0.81 | USP2 (0.54) | USP2SLCO1B1SLC7A5GABRR1SLC1A3 | |
| SCHEMBL1854670 | 0.81 | USP2 (0.54) | USP2SLCO1B1SLC7A5GABRR1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760881-B1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | NOSOPHARM (FR) | 2017-11-01 | — | — | EP | claimed |
| US-9260481-B2 | Peptide derivatives as antibiotics | NOSOPHARM (FR) | 2016-02-16 | — | — | US | claimed |
| US-20150175659-A1 | Peptide Derivatives as Antibiotics | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2015-06-25 | — | — | US | claimed |
| EP-2760881-A1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | Nosopharm (FR) | 2014-08-06 | — | — | EP | claimed |
| WO-2013045600-A1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | NOSOPHARM (FR) | 2013-04-04 | — | — | WO | claimed |
| EP-2760881-B1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | NOSOPHARM (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-9260481-B2 | Peptide derivatives as antibiotics | NOSOPHARM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20150175659-A1 | Peptide Derivatives as Antibiotics | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2760881-A1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | Nosopharm (FR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045600-A1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | NOSOPHARM (FR) | 2013-04-04 | — | — | WO | disclosed |
| US-6613738-B1 | Comprising 1,2-dihydroxy-homotyrosine, 4-hydroxyproline, threonine, glutamine, 3-,4-dihydroxymethylproline, 4,5-dihydroxyornithine and lipid | HMV CORPORATION | 2003-09-02 | — | — | US | disclosed |
| WO-2000009735-A1 | A CYCLIC LIPOPEPTIDE FROM CRYPTOSPORIOPSIS QUERCINA POSSESSING ANTIFUNGAL ACTIVITY | STROBEL GARY A (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175659-A1 | Peptide Derivatives as Antibiotics | VIP, NGLY1, NRDC | USP2 2008/4885SLCO1B1 2441/4885SLC7A5 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.